Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (Parkinson's disease, Alzheimer's disease and other cognitive disorders, bipolar disorder, and alcohol and drug dependence) and inflammatory diseases (rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease and others). It has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential.

Partnerships with top-tier pharmaceutical partners are in place for several programs as well as a strategic collaboration with UCB Pharma S.A. Biotie's most advanced product, nalmefene for alcohol dependence, has completed Phase 3 clinical development by licensing partner H. Lundbeck A/S.

Biotie currently has commercial collaborations with Lundbeck, UCB Pharma, Roche and Seikagaku Corp.

We seek to enter partnerships for products where collaboration adds expertise and additional resources, particularly for those products where specialist expertise is required or that target markets with a large, primary care component such as our VAP-1 antibody for inflammatory disease and our small-molecule PDE4 inhibitor, ronomilast, for chronic obstructive pulmonary disease (COPD).